Practical approach to anticoagulation for cardiopulmonary bypass in the patient with congenital prolonged activated partial thromboplastin time

Lana Cankovic, Brad L. Steenwyk, David C. McGiffin, Vance G Nielsen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Patients with rare, congenital deficiencies of contact proteins (e.g., factor XII, prekallikrein, high-molecular-weight kininogen) present an important challenge with regard to safe anticoagulation during cardiopulmonary bypass. Specifically, activated coagulation time values are obtained with devices that utilize contact protein activators to generate thrombin and assess the efficacy of heparin-mediated antithrombin activation, with an activated coagulation time value of 480 s considered 'safe'. Patients with contact protein deficiencies will routinely have activated coagulation time values that exceed normal baseline values to an unpredictable extent, which, when coupled with heparin administration may well exceed 480 s but still potentially not reflect adequate antithrombin activation. We present the successful management of anticoagulation of a patient with either a prekallikrein or kininogen deficiency during cardiopulmonary bypass for coronary artery bypass graft surgery with Hepcon-based heparin concentration determinations. This approach, and the other alternatives previously mentioned, can be utilized to safely care for these rare patients in the setting of cardiac surgery.

Original languageEnglish (US)
Pages (from-to)725-726
Number of pages2
JournalBlood Coagulation and Fibrinolysis
Volume19
Issue number7
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Partial Thromboplastin Time
Cardiopulmonary Bypass
Prekallikrein
Heparin
Protein Deficiency
Antithrombins
High Molecular Weight Kininogens
Kininogens
Factor XII
Coronary Artery Bypass
Thrombin
Thoracic Surgery
Patient Care
Reference Values
Transplants
Equipment and Supplies
Proteins

Keywords

  • Anticoagulation
  • Cardiopulmonary bypass
  • Kininogen
  • Prekallikrein

ASJC Scopus subject areas

  • Hematology

Cite this

Practical approach to anticoagulation for cardiopulmonary bypass in the patient with congenital prolonged activated partial thromboplastin time. / Cankovic, Lana; Steenwyk, Brad L.; McGiffin, David C.; Nielsen, Vance G.

In: Blood Coagulation and Fibrinolysis, Vol. 19, No. 7, 10.2008, p. 725-726.

Research output: Contribution to journalArticle

@article{95c44f09e4ce4406862bbd855cf88c9b,
title = "Practical approach to anticoagulation for cardiopulmonary bypass in the patient with congenital prolonged activated partial thromboplastin time",
abstract = "Patients with rare, congenital deficiencies of contact proteins (e.g., factor XII, prekallikrein, high-molecular-weight kininogen) present an important challenge with regard to safe anticoagulation during cardiopulmonary bypass. Specifically, activated coagulation time values are obtained with devices that utilize contact protein activators to generate thrombin and assess the efficacy of heparin-mediated antithrombin activation, with an activated coagulation time value of 480 s considered 'safe'. Patients with contact protein deficiencies will routinely have activated coagulation time values that exceed normal baseline values to an unpredictable extent, which, when coupled with heparin administration may well exceed 480 s but still potentially not reflect adequate antithrombin activation. We present the successful management of anticoagulation of a patient with either a prekallikrein or kininogen deficiency during cardiopulmonary bypass for coronary artery bypass graft surgery with Hepcon-based heparin concentration determinations. This approach, and the other alternatives previously mentioned, can be utilized to safely care for these rare patients in the setting of cardiac surgery.",
keywords = "Anticoagulation, Cardiopulmonary bypass, Kininogen, Prekallikrein",
author = "Lana Cankovic and Steenwyk, {Brad L.} and McGiffin, {David C.} and Nielsen, {Vance G}",
year = "2008",
month = "10",
doi = "10.1097/MBC.0b013e32830891ab",
language = "English (US)",
volume = "19",
pages = "725--726",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Practical approach to anticoagulation for cardiopulmonary bypass in the patient with congenital prolonged activated partial thromboplastin time

AU - Cankovic, Lana

AU - Steenwyk, Brad L.

AU - McGiffin, David C.

AU - Nielsen, Vance G

PY - 2008/10

Y1 - 2008/10

N2 - Patients with rare, congenital deficiencies of contact proteins (e.g., factor XII, prekallikrein, high-molecular-weight kininogen) present an important challenge with regard to safe anticoagulation during cardiopulmonary bypass. Specifically, activated coagulation time values are obtained with devices that utilize contact protein activators to generate thrombin and assess the efficacy of heparin-mediated antithrombin activation, with an activated coagulation time value of 480 s considered 'safe'. Patients with contact protein deficiencies will routinely have activated coagulation time values that exceed normal baseline values to an unpredictable extent, which, when coupled with heparin administration may well exceed 480 s but still potentially not reflect adequate antithrombin activation. We present the successful management of anticoagulation of a patient with either a prekallikrein or kininogen deficiency during cardiopulmonary bypass for coronary artery bypass graft surgery with Hepcon-based heparin concentration determinations. This approach, and the other alternatives previously mentioned, can be utilized to safely care for these rare patients in the setting of cardiac surgery.

AB - Patients with rare, congenital deficiencies of contact proteins (e.g., factor XII, prekallikrein, high-molecular-weight kininogen) present an important challenge with regard to safe anticoagulation during cardiopulmonary bypass. Specifically, activated coagulation time values are obtained with devices that utilize contact protein activators to generate thrombin and assess the efficacy of heparin-mediated antithrombin activation, with an activated coagulation time value of 480 s considered 'safe'. Patients with contact protein deficiencies will routinely have activated coagulation time values that exceed normal baseline values to an unpredictable extent, which, when coupled with heparin administration may well exceed 480 s but still potentially not reflect adequate antithrombin activation. We present the successful management of anticoagulation of a patient with either a prekallikrein or kininogen deficiency during cardiopulmonary bypass for coronary artery bypass graft surgery with Hepcon-based heparin concentration determinations. This approach, and the other alternatives previously mentioned, can be utilized to safely care for these rare patients in the setting of cardiac surgery.

KW - Anticoagulation

KW - Cardiopulmonary bypass

KW - Kininogen

KW - Prekallikrein

UR - http://www.scopus.com/inward/record.url?scp=55049106149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049106149&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e32830891ab

DO - 10.1097/MBC.0b013e32830891ab

M3 - Article

C2 - 18832918

AN - SCOPUS:55049106149

VL - 19

SP - 725

EP - 726

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 7

ER -